Plasma Tenascin-C: a novel prognostic biomarker in heart failure with preserved ejection fraction

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Prathap Kanagala

Liverpool University Hospitals NHS Trust, Liverpool (United Kingdom of Great Britain & Northern Ireland)

10 More presentations in this session

Presentation thumbnail

Role of neprilysin in myocardial tissue Renin-Angiotensin-System (RAS) of the failing heart

Doctor N. Pavo (Vienna, AT)

Presentation thumbnail

The value of tubular maximum phosphate reabsorption capacity, a functional proximal tubular parameter in heart failure

Ms L. Emmens (Groningen, NL)

Abstract Slides Video

Presentation thumbnail

The risk of bias of current novel circulating biomarker studies for the detection of HFpEF and left ventricular diastolic dysfunction

Mr M. Henkens (Maastricht, NL)

Abstract Slides Video

Presentation thumbnail

The effect of liraglutide on natriuretic peptides and copeptin in heart failure patients

Doctor R. Nielsen (Aarhus, DK)

Abstract Slides Video

Presentation thumbnail

Improvement of existing strategies to prevent heart failure after myocardial infarction: a potential role for thrombopoietin

Associate Professor L. Malinova (Saratov, RU)

Abstract Slides Video

Access the full session

Session thumbnail

Rapid Fire 2 - Biomarker: present and future

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Pharmacotherapy in HFpEF: where do cardiometabolic drugs fit in?

Congress Session

Clinical phenotypes of heart failure with preserved ejection fraction

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources